Mes: agosto 2020

TSX: WEF

VANCOUVER, BC, Aug. 7, 2020 /PRNewswire/ – Western Forest Products Inc. (TSX: WEF) («Western» or the «Company») announced today that it has received approval from the Toronto Stock Exchange («TSX») to renew a normal course issuer bid («NCIB») to purchase for cancellation up to 18,759,858 of its common shares, representing approximately 5% of the 375,197,166 common shares issued and outstanding as of August 6, 2020.

The NCIB, which will begin on August 11, 2020 and end no later than August 10, 2021, unless completed or terminated earlier, will be conducted through open market transactions through the facilities of the TSX or other Canadian marketplaces or alternative trading systems and will conform to their rules and regulations. The price to be paid by Western for any common share will be the market price at the time of acquisition.

The average daily trading volume of Western’s common shares over the six month period ending July 31, 2020, as calculated per the TSX rules, was 1,073,331 common shares. Consequently, under TSX rules, Western will be allowed to purchase daily, through the facilities of the TSX, a maximum of 268,332 common shares representing 25% of such average daily trading volume, subject to certain exceptions for block purchases. All shares purchased pursuant to the NCIB will be cancelled.

The Company has also entered into an automatic share purchase plan (the «Plan») with its designated broker to facilitate purchases of its common shares under the NCIB at times when the Company would ordinarily not be permitted to purchase its common shares due to regulatory restrictions or self-imposed blackout periods. Pursuant to the Plan, before entering a blackout period, Western may, but is not required to, instruct its broker to make purchases under the NCIB during the blackout period based on parameters established by Western in accordance with the rules of the TSX, applicable securities law and the terms of the Plan. Outside of restricted or self-imposed blackout periods, common shares may be purchased under the NCIB at the discretion of Western in accordance with TSX rules and applicable securities law. The Company’s current NCIB to purchase for cancellation up to 18,763,888 common shares expires on August 7, 2020. As of the close of trading on August 6, 2020, the Company has not purchased any common shares under its current NCIB.

The Company believes that, from time to time, the market price of its common shares may be attractive and their purchase would represent a desirable use of its capital to increase shareholder value.

About Western Forest Products Inc.

Western is an integrated forest products company building a margin-focused log and lumber business to compete successfully in global softwood markets. With operations and employees located primarily on the coast of British Columbia and Washington State, Western is a premier supplier of high-value, specialty forest products to worldwide markets. Western has a lumber capacity in excess of 1.1 billion board feet from eight sawmills and four remanufacturing facilities. The Company sources timber from its private lands, long-term licenses, First Nations arrangements, and market purchases. Western supplements its production through a wholesale program providing customers with a comprehensive range of specialty products.

Forward-looking Statements

This press release contains statements that may constitute forward-looking statements under the applicable securities laws. Readers are cautioned against placing undue reliance on forward-looking statements. All statements herein, other than statements of historical fact, may be forward-looking statements and can be identified by the use of words such as «will», «may» and similar references to future periods. Although such statements reflect management’s current reasonable beliefs, expectations and assumptions, there can be no assurance that forward-looking statements are accurate, and actual results or performance may materially vary. Many factors could cause our actual results or performance to be materially different, including a change in the Company’s financial situation, general economic conditions and other factors referenced under the «Risks and Uncertainties» section of our MD&A in our 2019 Annual Report dated February 11, 2020.

View original content to download multimedia:http://www.prnewswire.com/news-releases/western-forest-products-inc-announces-renewal-of-normal-course-issuer-bid-301108133.html

SOURCE Western Forest Products Inc.

FRANKLIN LAKES, New Jersey, Aug. 7, 2020 /PRNewswire-HISPANIC PR WIRE/ — BD (Becton, Dickinson and Company), a leading global medical technology company, announced a voluntary recall on June 23, 2020 for specified catalog numbers of the ChloraPrep^™ 3 mL applicator due to possible fungal contamination, which only affects climate zone IV regions in specific U.S. territories and countries (see list of catalog numbers and regions impacted by this issue below).

BD has identified that storage of the ChloraPrep^™ 3 mL Applicator in regions of the world with high heat and humidity, where product may be consistently exposed to temperatures of 30 degrees Celsius (86 degrees Fahrenheit) and 75% relative humidity for more than six months, may result in the growth of Aspergillus penicillioides. The recall does not apply to any states in the United States, it only applies to the U.S. territories of Puerto Rico, Guam, U.S. Virgin Islands, Northern Mariana Islands and American Samoa.

This recall does not include 3 mL applicators found in kits. It also does not include any other ChloraPrep™ product presentations. All other ChloraPrep™ products are manufactured with different packaging materials that are not affected by this issue.

As part of the voluntary recall to the user level, the company notified customers and distributors affected by the recall and provided guidance on the potential impact when the affected products were used.

Through internal product quality testing, BD has identified that storage of the ChloraPrep™ 3 mL Applicators where product may be consistently exposed to temperatures of 30 degrees Celsius (86 degrees Fahrenheit) and 75% relative humidity for more than six months can result in the growth of Aspergillus penicillioides, a type of fungus, resulting in a breach in the outer package integrity.

The Aspergillus penicillioides within the packaging can contaminate the surface of the applicator and/or gloved hands of the health care professional and then consequently the sterile field. Contamination of skin preparation products with Aspergillus penicillioides may lead to serious systemic infection, sepsis, illness and death. If the fungus is introduced into the patient’s bloodstream during placement of an intravascular catheter, the catheter would most likely have to be removed, necessitating another procedure. Aspergillus penicillioides infection of a surgical site may result in the need for medical and surgical interventions and long-term treatment with antifungal drugs.

To date, no complaints, adverse events, injuries or deaths have been reported related to this voluntary recall.

At the time of the recall, BD informed customers and distributors in the affected territories to discard all remaining inventory of the impacted ChloraPrep™ 3 mL applicators (see list of impacted catalog numbers below) and committed to replacing product affected by the recall.

This recall is limited to the U.S. territories and countries listed above. This recall does not affect any other ChloraPrep™ product presentations, regardless of geography.

Customer inquiries related to this recall, as well as adverse reaction/events experienced with the product should be addressed to BD Customer Support: 1-800-526-4455 (Toll Free) between the hours of 8:30 a.m. and 6 p.m. ET.

FDA MedWatch Reporting
Adverse reactions/events experienced with the use of any of these products should also be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

• Complete and submit the report Online: www.fda.gov/medwatch/report.htm
• Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.

Logo – https://mma.prnewswire.com/media/617615/BD_Logo.jpg

SOURCE BD (Becton, Dickinson and Company)